This policy outlines how the College complies with UK Data Protection legislation.
Establishing a correct diagnosis of Ehlers Danlos Syndrome hypermobility type (hEDS) in children and adolescents – position statement
The purpose of this position statement is to clarify the current criteria in making a diagnosis of hEDS in children and adolescents and to provide advice to paediatric health professionals in relation to provision of appropriate rehabilitation.
The use of unlicensed medicines or licensed medicines for unlicensed applications in paediatric practice
This statement, originally produced in 2000, was updated in 2013 by the Joint Standing Committee on Medicines, a committee of the Royal College of Paediatrics and Child Health and the Neonatal and Paediatric Pharmacists Group. The update reflects changes in European (including UK) law that aim to fa...
The aim of this evidence-based statement is to summarise the current knowledge about delayed prescriptions (also called backup prescriptions) for antibiotics and to highlight the special issues that must be taken into account when considering the need for a delayed prescription in infants and childr...
The Neonatal and Paediatric Pharmacists Group (NPPG) and the Royal College of Paediatrics and Child Health (RCPCH) strongly recommend that when children require unlicensed liquid medications, they should receive the RCPCH and NPPG recommended strength, where one exists. There are currently 12 such r...